TherapeuticsMD, Inc. (TXMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 25M 50M 75M FY11: 2.1M FY12: 3.8M FY13: 8.8M FY14: 15M FY15: 20.1M FY16: 19.4M FY17: 16.8M FY18: 16.1M FY19: 49.6M FY20: 64.9M FY21: 2.6M FY22: 70M FY23: 1.3M FY24: 1.8M FY25: 3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 25M 50M 75M FY11: 1.1M FY12: 2.5M FY13: 6.8M FY14: 11.4M FY15: 15.6M FY16: 15.2M FY17: 14.1M FY18: 13.4M FY19: 43.3M FY20: 48.9M FY21: 1.2M FY22: 68.6M FY23: 1.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23

Operating Income Annual

-180M -120M -60M 0 60M 120M 180M FY11: -5.4M FY12: -16.1M FY13: -25.8M FY14: -54M FY15: -85.2M FY16: -90.3M FY17: -77.6M FY18: -130.2M FY19: -151.2M FY20: -155.5M FY21: -79.6M FY22: 1.2M FY23: -8.5M FY24: -6.1M FY25: -4.4M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-210M -140M -70M 0 70M 140M 210M FY10: -2.9M FY11: -12.9M FY12: -35.1M FY13: -28.4M FY14: -54.2M FY15: -85.1M FY16: -89.9M FY17: -76.9M FY18: -132.6M FY19: -176.1M FY20: -183.5M FY21: -172.4M FY22: 112M FY23: -10.3M FY24: -2.2M FY25: -569K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 6M 12M 18M FY16: 4.2M FY17: 2.6M FY18: 2.7M FY19: 6.3M FY20: 16M FY21: 1.4M FY22: 1.4M FY16 FY17 FY18 FY19 FY20 FY21 FY22

Operating Cash Flow Annual

-180M -120M -60M 0 60M 120M 180M FY11: -5M FY12: -12.7M FY13: -20.8M FY14: -45.5M FY15: -79M FY16: -69.1M FY17: -76.2M FY18: -106.8M FY19: -165.7M FY20: -159.5M FY21: -142.7M FY22: 9.4M FY23: -23.1M FY24: 1.2M FY25: 2.5M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-180M -120M -60M 0 60M 120M 180M FY11: -5M FY12: -12.8M FY13: -20.8M FY14: -45.6M FY15: -79.2M FY16: -69.5M FY17: -76.2M FY18: -107M FY19: -168.2M FY20: -159.7M FY21: -142.7M FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 100M 200M 300M FY19: 246.4M FY20: 275.6M FY21: 8M FY22: 9.4M FY23: 10.4K FY24: 11.5M FY25: 11.6M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '11: -0.21 Q1 '12: -0.36 Q2 '12: -0.48 Q3 '12: -0.49 Q4 '12: -0.40 Q1 '13: -0.30 Q2 '13: -0.21 Q3 '13: -0.23 Q4 '13: -0.23 Q1 '14: -0.23 Q2 '14: -0.25 Q3 '14: -0.31 Q4 '14: -0.35 Q1 '15: -0.42 Q2 '15: -0.51 Q3 '15: -0.50 Q4 '15: -0.50 Q1 '16: -0.48 Q2 '16: -0.43 Q3 '16: -0.45 Q4 '16: -0.47 Q1 '17: -0.47 Q2 '17: -0.46 Q3 '17: -0.40 Q4 '17: -0.38 Q1 '18: -0.38 Q2 '18: -0.43 Q3 '18: -0.52 Q4 '18: -0.59 Q1 '19: -0.64 Q2 '19: -0.72 Q3 '19: -0.69 Q4 '19: -0.71 Q1 '20: -0.34 Q2 '20: -0.30 Q3 '20: -0.29 Q4 '20: -0.25 Q1 '21: -6.13 Q2 '21: -11.35 Q3 '21: -16.85 Q4 '21: -21.68 Q1 '22: -21.71 Q2 '22: -3.47 Q3 '22: -0.98 Q4 '22: 12.10 Q1 '23: 17.43 Q2 '23: 4.36 Q3 '23: 7.17 Q4 '23: -1.00 Q1 '24: -0.69 Q2 '24: -0.54 Q3 '24: -0.27 Q4 '24: -0.19 Q3 '12 Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.